The company projects 2025 sales growth between 3% and 5%, driven by consumer-oriented segments and improving industrial trends. Consumer & Specialties is expected to grow 4%-8%, supported by new ...

Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the ...

GSK's oncology sales increased 98% in 2024, and reflects strong demand and potentially new launches or indications for cancer therapies.

Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Mesoblast (MESO) to $24 from $15 and keeps an Overweight rating on the ...

The following is a summary of “Underutilized treatments for patients with refractory cancer pain: A qualitative study assessing the use of intrathecal drug delivery devices in the United Kingdom ...

The following is a summary of “Chronic graft-versus-host disease myelitis successfully treated with rituximab,” published in ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

A Pennsylvania refractory brick manufacturer won its lawsuit against the securities broker it says orchestrated a fraudulent scheme to siphon $5.7 million from its pension plan.

In this video, Sham Mailankody, MBBS discusses the specific challenges that come with treating relapsed/refractory multiple myeloma.

Kuro Oncology and partner Kyowa Kirin are on track for an NDA submission for ziftomenib in the second quarter of this year.

Metronomic chemotherapy (MC) is emerging as a groundbreaking treatment for pediatric neuroblastoma, offering a more accessible and manageable option for children with high-risk and relapsed/refractory ...

During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...